^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Ac-225 rosopatamab tetraxetan (CONV01-α)

    i
    Associations
    News

    Trials

    Company:
    Dominari Holdings, Weill Cornell Medical College
    Drug class:
    Alpha radiation emitter, PSMA inhibitor
    Related drugs:
    Associations
    News

    Trials

    Apply
    Re-treatment 225Ac-J591 for mCRPC (NCT04576871)
    Phase 1
    Weill Medical College of Cornell University
    Recruiting
    Last update posted :
    10/31/2023
    Initiation :
    10/29/2020
    Primary completion :
    12/31/2025
    Completion :
    12/31/2026
    CYP17A1
    |
    Ac-225 rosopatamab tetraxetan (CONV01-α)
    Fractionated and Multiple Dose 225Ac-J591 for Progressive mCRPC (NCT04506567)
    Phase 1/2
    Weill Medical College of Cornell University
    Recruiting
    Last update posted :
    08/28/2023
    Initiation :
    08/18/2020
    Primary completion :
    06/30/2025
    Completion :
    06/30/2027
    CYP17A1
    |
    Ac-225 rosopatamab tetraxetan (CONV01-α)
    ACTInium-J591 Radionuclide Therapy in PSMA-Detected Metastatic HOrmone-Sensitive Recurrent Prostate CaNcer (ACTION) (NCT05567770)
    Phase 1
    Weill Medical College of Cornell University
    Withdrawn
    Last update posted :
    08/24/2023
    Initiation :
    12/01/2023
    Primary completion :
    01/01/2025
    Completion :
    01/01/2030
    FOLH1
    |
    FOLH1 expression
    |
    Ac-225 rosopatamab tetraxetan (CONV01-α)
    Phase I/II 225Ac-J591 Plus 177Lu-PSMA-I&T for Progressive Metastatic Castration Resistant Prostate Cancer (NCT04886986)
    Phase 1/2
    Weill Medical College of Cornell University
    Suspended
    Last update posted :
    08/21/2023
    Initiation :
    06/30/2021
    Primary completion :
    12/24/2024
    Completion :
    12/27/2027
    CYP17A1
    |
    lutetium zadavotide guraxetan (PNT2002) • Ac-225 rosopatamab tetraxetan (CONV01-α)